 are a major component of costs of treatment. As additional devices have been introduced to the
market, it had been speculated that competition would
lower price and incentivize further innovation. However,
a decrease in device cost has not been observed. Several
institutions have reported that EVAR confers a negative
operating margin in Medicare beneÔ¨Åciaries.773,774
Whereas cost-effectiveness results can vary among
different populations of patients and health care systems
and